EAVESDROPPING IN HOUSTON

Overheard: Houston experts weigh in on the future of the Space City

The panel of experts discussed the Space City's history — but also its future as a leader in space exploration. Photo courtesy of SpaceCom

Houston's been known as the Space City for about 50 years since "Houston" was the first word spoken from the surface of the moon. But whether or not that nickname will continue to stick was up for debate at a 2019 SpaceCom panel on November 21.

The panel, entitled "Regional Benefits of a Commercial Space Economy: Case Study Houston," the panelists set out to discuss the city's rich history of space exploration, as well as to answer the question of where Houston's space industry is headed.

"We could ask that question in a passive way, but my preference is that here in Houston we ask the question now, answer it, and be very proactive and deliberate about making sure we get the outcome that we want," says Vernon McDonald, senior vice president at KBR and moderator of the discussion.

If you missed the enlightening discussion, here are a few takeaways from the panelists.

"Houston is in this great position to be this beacon to lead entrepreneurs and inspire other regions to explore further."

Rick Jenet, director of the Center for Advanced Radio Astronomy. Jenet, who is based in Brownsville, Texas, is working to develop a vibrant commercial space hub in South Texas. In a lot of ways, the area looks to Houston's history for its development, he says.

"We built a community of engineers and scientists and a workforce that's all vested in the outcome of the human space flight program."

Steve Altemus, president and CEO of Intuitive Machines. The creation of the Johnson Space Center developed generations within the community of scientists and engineers, but, moving forward, Houston has to be intentional about building its talent base. "I'm very passionate about doing that here in Houston," Altemus adds.

"There's a beacon of hope for our community if we can organize around it and attract commercial business here to keep this city the Space City, but redefine ourselves as a commercial space hub."

Altemus says, adding that it's going to take further development, talent, and funds — like what's happening at the Houston Spaceport — to make this transition.

"Over the years, Houston took space for granted. Houston started to focus on the bigger industries that brought in funding and jobs."

Steven Gonzalez, technology transfer strategist at NASA's Johnson Space Center. At the risk of being unpopular, Gonzalez mentions that the city's attention has been diverted from space exploration. However, he adds, there are new initiatives from the Greater Houston Partnership and Houston First that are picking up the slack.

"The answers to Houston delivering on its potential is going to be collaborations — how well we collaborate."

Harvin Moore, president at Houston Exponential. Houston is collaborative, and the city needs to make sure its resources are inclusive as commercial space develops in town.

"I'd like to say that Houston is the birthplace of human space flight, and in 50 years, I'd like to see the city be the leader and the point of the spirit for human exploration internationally and commercially out in mars and beyond.

Altemus responds when asked about the Space City's next 50 years.

"I think what Houston will be most proud of in 50 years is that we played an extremely important role in shaping how Texas leads the world in commercial space exploration."

Jenet, who mentions that there's space exploration innovation happening statewide.

"When you think about what [leading space exploration] company will be here fifty years from now, I don't think it's been created yet. But I would like that company to be here in Houston."

Gonzalez says, adding that the first trillionaire is likely to make his or her fortune in the space industry, and he wants that money here in Houston.

"A lot of our future is not going to be based on what huge companies or government are doing but much more about entrepreneurs."

Moore says, emphasizing the need for developing startup resources in Houston.

Trending News

 
 

Promoted

Dr. Darren G. Woodside (right), Dr. Ronald J. Biediger, and their team at the Texas Heart Institute received a $1.14 million grant from The National Heart, Lung, and Blood Institute to develop a novel, first-in-class drug. Photo via texasheart.org

Atherosclerosis is a prime pathway to heart attack, heart failure, and stroke. In fact, one in every five deaths recorded in 2021 was due to cardiovascular disease, much of which was caused by atherosclerosis. The thickening and hardening of arteries due to plaque buildup causes the blood vessels to narrow and block blood flow. That leads to the chronic inflammation that causes cardiac events due to atherosclerotic plaque rupture or erosion.

But what if we could lower that inflammation and cut those cardiac incidents off at the pass? Last week, The Texas Heart Institute announced that it had received a two-year, $1.14 million grant from The National Heart, Lung, and Blood Institute to develop a novel, first-in-class drug to treat the cardiovascular disease that arises from atherosclerosis.

“Given the sobering mortality statistics associated with heart disease, a novel therapy that could change disease trajectory and delay or prevent events associated with atherosclerotic cardiovascular disease would be a significant improvement to current treatment regimens,” Dr. Darren G. Woodside, vice president for research, senior investigator, and director of the Flow Cytometry and Imaging Core at The THI, says in a press release.

The most common way to prevent an adverse event is through prescribing patients a statin drug, which lowers lipids. There is ample evidence that this isn’t enough to prevent an incident and most current treatments for atherosclerosis are targeted at helping patients only after plaque rupture has already occurred.

The new technology being developed by THI is focused on a new strategy that will suppress white blood cell activation within atherosclerotic plaques before plaque rupture can take place.

Woodside’s co-principal investigator is Dr. Ronald J. Biediger, director of Medicinal Chemistry at THI. Alongside other members of the Molecular Cardiology Research Laboratories at THI, the two doctors are responsible for the technologies that could lead to drug development.

“If successful, our approach would represent a first-in-class therapeutic, as no drugs marketed today take advantage of this specific strategy of targeting integrin signaling through Syk,” says Dr. Woodside, referring to the intracellular protein important to the production of interleukin.

This is just the latest news THI has to celebrate. Earlier this month, the organization received a $32 million donation received a $32 million donation from a patient — the largest charitable donation in its history. Shortly after that news came out, the institute announced a new partnership with the University of Houston Tilman J. Fertitta Family College of Medicine that allows those UH medical students to join a clinical rotation at The Texas Heart Institute. The alliance means valuable insights and experience with both inpatient and outpatient cardiology for UH's future doctors.

Dr. Joseph Rogers, president and CEO of THI, shared on the Houston Innovators Podcast his dedication to THI's 60-year legacy and continuing to find new ways to reach heart health care patients.

"Despite all of the advances, cardiovascular disease is still one of the largest killers of Americans. It actually kills more Americans than all types of cancer combined," Rogers says on the show.


Trending News

 
 

Promoted